# Chong Kun Dang Pharmaceutical clinical trials: 299 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 299 trials with Chong Kun Dang Pharmaceutical as lead sponsor, 10 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chong Kun Dang Pharmaceutical: 299 rows for $14.95, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chong-kun-dang-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 299
- Recruiting or not yet: 10
- Read on: November 19, 2026

## Trials

The 25 newest of 299, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 6, 2026 | NCT07748702 | Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Hypertension | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748702) |
| April 15, 2026 | NCT07532148 | Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Chong Kun Dang Pharmaceutical | Phase 1 | Not yet recruiting | Ovarian Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532148) |
| February 27, 2026 | NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | Chong Kun Dang Pharmaceutical | Phase 1/2 | Recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439094) |
| February 11, 2026 | NCT07404735 | A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Benign Prostate Hypertrophy(BPH) | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07404735) |
| January 26, 2026 | NCT07365358 | Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients | Chong Kun Dang Pharmaceutical | Phase 4 | Not yet recruiting | Diabete Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365358) |
| January 22, 2026 | NCT07358156 | A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in... | Chong Kun Dang Pharmaceutical | Phase 1 | Recruiting | Atopic Dermatitis | 519 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358156) |
| December 26, 2025 | NCT07304726 | Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type 2 Diabetes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304726) |
| December 26, 2025 | NCT07304700 | Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type 2 Diabetes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304700) |
| December 26, 2025 | NCT07304687 | Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type 2 Diabetes | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304687) |
| December 2, 2025 | NCT07258745 | Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and... | Chong Kun Dang Pharmaceutical | Phase 1 | Recruiting | Psoriasis | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258745) |
| October 10, 2025 | NCT07215637 | Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors | Chong Kun Dang Pharmaceutical | Phase 1 | Recruiting | Advanced Solid Tumors, Metastatic Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215637) |
| May 20, 2025 | NCT06979973 | A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult... | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06979973) |
| May 16, 2025 | NCT06974903 | Retrospective Observational Study on GERD Management in General Hospitals in Korea | Chong Kun Dang Pharmaceutical | Observational | Completed | Gastroesophageal Reflux Disease (GERD) | 13,750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06974903) |
| May 2, 2025 | NCT06954766 | Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981 | Chong Kun Dang Pharmaceutical | Phase 2 | Completed | Knee Osteoarthritis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06954766) |
| April 24, 2025 | NCT06942156 | Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea | Chong Kun Dang Pharmaceutical | Phase 4 | Not yet recruiting | Heart Transplant | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06942156) |
| April 8, 2025 | NCT06916793 | A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia | Chong Kun Dang Pharmaceutical | Phase 3 | Recruiting | Androgenetic Alopecia | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06916793) |
| February 20, 2025 | NCT06838286 | Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes | Chong Kun Dang Pharmaceutical | Observational | Recruiting | Diabetes Mellitus, Type 2 | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06838286) |
| January 6, 2025 | NCT06758661 | Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Dyslipidemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758661) |
| December 10, 2024 | NCT06727396 | A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Healthy Subjects | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06727396) |
| November 29, 2024 | NCT06709807 | Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06709807) |
| November 19, 2024 | NCT06695598 | Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06695598) |
| November 19, 2024 | NCT06695572 | Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06695572) |
| October 22, 2024 | NCT06652971 | A Clinical Trial to Evaluate the Food Effect of CKD-379 | Chong Kun Dang Pharmaceutical | Phase 1 | Completed | Type II Diabetes Mellitus | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06652971) |
| October 16, 2024 | NCT06643819 | Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A | Chong Kun Dang Pharmaceutical | Phase 3 | Recruiting | Essential Hypertension | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06643819) |
| July 9, 2024 | NCT06492655 | To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers | Chong Kun Dang Pharmaceutical | Phase 1 | Unknown | Type 2 Diabetes Mellitus | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492655) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 203 |
| Phase 1/2 | 2 |
| Phase 2 | 17 |
| Phase 3 | 36 |
| Phase 4 | 36 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 219 |
| Unknown | 68 |
| Recruiting | 7 |
| Not yet recruiting | 3 |
| Terminated | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 58 |
| Diabetes Mellitus, Type 2 | 52 |
| Dyslipidemias | 41 |
| Essential Hypertension | 18 |
| Cardiovascular Diseases | 10 |
| Gastroesophageal Reflux | 9 |
| Hyperlipidemias | 8 |
| Prostatic Hyperplasia | 7 |
| Hepatitis B, Chronic | 6 |
| Arthritis, Rheumatoid | 5 |
| Angina, Stable | 5 |
| Heart Failure | 5 |
| Alopecia | 4 |
| Multiple Myeloma | 3 |
| Osteoarthritis, Knee | 3 |
| Glaucoma, Open-Angle | 3 |
| Ocular Hypertension | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Metabolic Diseases | 3 |
| Glaucoma | 2 |
| Dry Eye Syndromes | 2 |
| Anemia | 2 |
| Coronary Artery Disease | 2 |
| COVID-19 | 2 |
| Gastritis | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Vehicle manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-manufacturers/united-states)
- [IT companies in the United States](https://specstream.ai/data/businesses/it-companies/united-states)
- [B2B transportation and storage companies in the United States](https://specstream.ai/data/businesses/b2b-transportation-and-storage-companies/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
- [Credit unions in the United States](https://specstream.ai/data/businesses/credit-unions/united-states)
